Physician profile
Bianca B Waldschmidt
NPI 1437651692
$6,525.95
in general payments reported to CMS, 2019-2025
22 companies · $1,759 in 2025
The $1,759 reported for 2025 was more than what 91% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $910 · 2022: $832 · 2023: $1,922 · 2024: $1,103 · 2025: $1,759.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,210 · Education: $575.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,210.09 |
| Education | $574.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,305.87 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $701.45 | 2022-2025 | Absorica Ld, Winlevi, Ilumya |
| Genzyme Corporation | $592.00 | 2022-2025 | |
| Galderma Laboratories, L.P. | $562.69 | 2021-2025 | Nemluvio |
| Ucb, INC. | $533.52 | 2021-2025 | Bimzelx, Cimzia |
| Novartis Pharmaceuticals Corporation | $497.85 | 2022-2025 | |
| Incyte Corporation | $458.20 | 2021-2024 | Opzelura |
| Janssen Biotech, INC. | $304.49 | 2021-2025 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $284.25 | 2023-2025 | Dupixent, Libtayo |
| Arcutis Biotherapeutics, INC. | $216.10 | 2023-2025 | Zoryve |
| Lilly USA, LLC | $197.02 | 2022-2025 | Olumiant, Taltz, Ebglyss |
| Amgen INC. | $150.87 | 2022-2025 | Otezla, Otezla |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $132.97 | 2021-2023 | Arazlo, Jublia, Duobrii |
| Vyne Pharmaceuticals INC. | $123.56 | 2021 | |
| Pfizer INC. | $111.57 | 2021-2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $103.39 | 2021-2023 | |
| Verrica Pharmaceuticals INC. | $66.25 | 2023-2024 | Ycanth |
| E.R. Squibb & Sons, L.L.C. | $52.25 | 2023-2025 | Sotyktu |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.91 | 2023 | Cyltezo |
| Biofrontera INC. | $40.63 | 2021-2023 | Xepi, Bf-Rhodoled, Ameluz |
| Organon LLC | $22.19 | 2025 | Vtama |
| Leo Pharma INC. | $20.92 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bianca Waldschmidt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.